Hanyang Med Rev.  2017 May;37(1):18-24. 10.7599/hmr.2017.37.1.18.

The role of PI3K/AKT pathway and its therapeutic possibility in Alzheimer's disease

Affiliations
  • 1Department of Neurology, Bundang Jesaeng Hospital, Gyeonggi, South Korea.
  • 2Department of Neurology, Hanyang University Guri Hospital, Gyeonggi, South Korea. ksh213@hanyang.ac.kr

Abstract

Alzheimer's disease (AD) is the most common form of dementia. Although uncountable clinical trials have been done to develop the treatment of AD, there are a couple of drugs that can be used only for symptomatic treatment. Therefore, many studies based on the amyloid cascade hypothesis and the tauopathy hypothesis are still ongoing. After the failure of numerous huge Phase III clinical trials, arguments on those hypotheses have arisen and efforts to establish other possible therapeutic strategies based on diverse plausible mechanisms associated with AD have been done as well. One of the new therapeutic targets for AD is the phosphatidylinositol 3-kinase (PI3K)/AKT pathway. In this review, questions on the two hypotheses, the definition of the PI3K/AKT pathway, the relationship between the pathway and AD, and the possibility of the modulation of the pathway as a new therapeutic strategy for AD will be discussed briefly.

Keyword

Alzheimer's disease; Phosphatidylinositol 3-kinase; AKT; Amyloid beta; Tau

MeSH Terms

Alzheimer Disease*
Amyloid
Dementia
Phosphatidylinositol 3-Kinase
Tauopathies
Amyloid
Phosphatidylinositol 3-Kinase
Full Text Links
  • HMR
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr